Asymchem Laboratories (Tianjin) Co., Ltd. provided earnings guidance for the year ended December 31, 2022. For the year, the company expects approximately RMB 3,293.35 million to­ RMB 3,346.82 million, representing an increase by approximately 208% to 213% of net profit attributable to shareholders of the Company. The " dual-wheel-drive " strategy was effectively implemented, accelerating the rapid development of emerging business sectors such as chemical macromolecules, clinical CRO, CDMO preparations and biological macromolecule CDMO.

During the Reporting Period, the number of customers and projects in each emerging business sector continued to grow. The Company's revenue generated from the emerging business sectors is estimated to have a year-on-year increase of more than 145%. The domestic market has entered into a harvest season, the customer pool of various businesses was further expanded, and late-stage clinical and commercialization projects continued to be realized.

The Company's revenue generated from the domestic market is estimated to have a year-on-year increase of more than 140%. Basic earnings per share of the Company approximately RMB 9.00 per share ­ RMB 9.20 per share. The operating revenue of the Company for the Reporting Period is estimated to be in a range between approximately RMB 10.113 billion and approximately RMB 10.345 billion, representing an increase by a range between approximately 118% and approximately 123%.

The Company has maintained its global leading position in small molecule CDMO and fully implemented lean management in 2022. Benefiting from the improvement in operational efficiency and the effective release of economies of scale, the continuous high-quality delivery of large orders boosted the rapid growth of annual results. During the Reporting Period, the reserve of late-stage clinical projects was ample and the potential of commercialization projects continued to be released.

The number of customers and projects of the Company continued to increase. The Company's revenue generated from its small molecule business is estimated to have a year-on-year increase of more than 115%. At the same time, the Company adhered to the technology-driven business strategy and the proportion of new technology application was further increased, boosting the improvement of profitability.